Abstract
The anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been shown to induce a response in lung cancers in which ALK is mutated. Crizotinib is also effective in anaplastic large-cell lymphoma, the tumor in which ALK rearrangement was initially detected.
Cite
CITATION STYLE
APA
Gambacorti-Passerini, C., Messa, C., & Pogliani, E. M. (2011). Crizotinib in Anaplastic Large-Cell Lymphoma. New England Journal of Medicine, 364(8), 775–776. https://doi.org/10.1056/nejmc1013224
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free